$EW News

$100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today

Does Valve Repair Approval Change The Bull Case For Edwards Lifesciences (EW)?

Edwards wins FDA approval for tricuspid valve repair device

Edwards secures FDA approval for tricuspid valve repair system

FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease

FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death

Edwards’ SAPIEN M3 delivery system linked to patient death in FDA alert

Reported Earlier, Edwards Lifesciences Tells Customers To Remove Four Lots Of Commander M Delivery Systems For SAPIEN M3; FDA Flags Potentially High-Risk Issue

Edwards Lifesciences Earnings Preview: What to Expect

Barclays Initiates Coverage of Edwards Lifesciences at Overweight

Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026

Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110

Edwards Lifesciences to Host Investor Event in Conjunction With TCT

Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve

Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients

Edwards Lifesciences Says FDA Approves AUTUS Size-Adjustable Valve, Surgical Pulmonary Valve Designed For Pediatric Patients With Congenital Heart Disease

How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions

Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion

Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead

Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript